Recent Updates
Recently added Catalysts
MGX Positive Sentiment

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Metagenomi Therapeutics is progressing towards submitting an investigational new drug application for MGX-001, aimed at treating hemophilia A, expected in the fourth quarter of 2026. The company reported having $120.7 million in cash and equivalents as of June 30, 2026, ensuring a solid financial runway for its upcoming clinical endeavors.

Market Sentiment Analysis

POSITIVE FACTORS

  • On track to submit IND application for MGX-001.
  • Focus on global clinical program for hemophilia A.
  • $120.7 million in cash and equivalents available.

Full Press Release Details

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to

Frequently Asked Questions

What is MGX-001?

MGX-001 is a therapeutic candidate being developed by Metagenomi for hemophilia A.

When will Metagenomi submit the IND application?

The IND application for MGX-001 is expected to be submitted in the fourth quarter of 2026.

What were Metagenomi's financial results for Q2 2026?

As of June 30, 2026, Metagenomi reported $120.7 million in cash and equivalents.

What is the focus of Metagenomi's clinical program?

The clinical program focuses on the treatment of hemophilia A.

ShareAdd on Google
Tags: MGX Viatris Investor Conferences Healthcare Metagenomi hemophilia A IND application financial results
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$140M liquidity · $7M/mo burn
~17 mo
Low dilution risk